Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Cardinal Health operates four reportable segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Clinical Technologies and Services. The company provides integrated solutions to health care providers, including distribution, manufacturing, and technology services.
Key Financial Metrics
All figures in millions, except per share data.
| Metric | Three Months Ended Mar 31, 2006 | Nine Months Ended Mar 31, 2006 |
|---|---|---|
| Revenue | $20,637.5 | $59,655.3 |
| Gross Margin | $1,369.2 (6.6%) | $3,853.5 (6.5%) |
| Operating Earnings | $559.4 | $1,432.4 |
| Net Earnings | $146.8 | $679.1 |
| Diluted EPS (Net) | $0.34 | $1.58 |
| Cash from Operating Activities | N/A | $1,656.7 |
| Cash and Equivalents (Balance Sheet) | $1,713.4 | $1,713.4 |
| Total Debt (Current + Long-term) | $2,828.9 | $2,828.9 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% year-over-year for both the three and nine-month periods, driven by growth in all four segments, particularly Pharmaceutical Distribution (10% growth) and Clinical Technologies (15% growth).
- Net Earnings Decline: Net earnings for the three months ended March 31, 2006, dropped 60% to $146.8 million from $365.7 million in the prior year. This decline was primarily due to a $209.0 million loss from discontinued operations (compared to an $8.8 million loss in the prior year) and increased equity-based compensation expenses.
- Discontinued Operations: The company reclassified significant portions of its Healthcare Marketing Services, Intercare Pharmaceutical Distribution, and Sterile Pharmaceutical Manufacturing businesses to discontinued operations, resulting in substantial impairment charges ($238.2 million for the nine months ended March 31, 2006).
- Equity-Based Compensation: Following the adoption of SFAS No. 123(R), equity-based compensation expense surged to $48.7 million for the quarter (from $2.2 million in the prior year) and $185.2 million for the nine months (from $7.2 million).
- Special Items: Total special items were $23.0 million for the quarter and $59.9 million for the nine months, including restructuring costs, merger-related costs, and litigation settlements (which provided a net benefit of $23.5 million for the nine months).
Guidance, Outlook, and Risks
- Management Commentary: Management expects the global restructuring program to be substantially completed by the end of fiscal 2008, aiming to improve operating earnings. Equity compensation expense for fiscal 2006 is now estimated at approximately $240 million, higher than the previously disclosed range due to recent management changes and SAR valuation.
- SEC Investigation: The company is engaged in settlement discussions with the SEC regarding accounting and financial reporting matters. An agreement-in-principle has been reached involving a $35 million penalty, with $35 million reserved ($25 million in FY2005 and $10 million in Q2 FY2006). Final terms are subject to Commission approval.
- Regulatory Risks: New Medicaid reimbursement legislation signed into law in February 2006 may adversely affect the Pharmaceutical Distribution segment starting January 1, 2007. The company is developing mitigation plans.
- Subsequent Events:
- On April 17, 2006, R. Kerry Clark was appointed President and CEO, with Robert D. Walter becoming Executive Chairman.
- The company announced the sale of a significant portion of its Specialty Distribution business to Oncology Therapeutics Network.
- Definitive agreements were signed to acquire Denver Biomedical, Inc. and the wholesale distribution business of The F. Dohmen Co.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the final sale terms and remaining liabilities associated with the Healthcare Marketing Services, Intercare, and Humacao operations classified as discontinued.
- SEC Settlement Finalization: Monitor the finalization of the $35 million SEC settlement and any potential additional penalties or restatements.
- Medicaid Legislation Impact: Assess the specific financial impact of the new Medicaid reimbursement formula on the Pharmaceutical Distribution segment's margins starting in 2007.
- Equity Compensation Trajectory: Track the actual equity-based compensation expense for the remainder of fiscal 2006 against the revised $240 million estimate.
- Specialty Distribution Sale: Confirm the closing of the Specialty Distribution sale and the resulting minority ownership stake in Oncology Holdings, Inc.